Notably, we also emphasize that inappropriate pharmacological management of comorbidities—such as diabetes, myeloid leukemia, and hypertension—may suppress sodium-iodide symporter (NIS) expression and RAI uptake, thereby contributing to RAIR development. This evidence concerns the gene SLC5A5 and hypertensive disorder.